<DOC>
	<DOCNO>NCT01455272</DOCNO>
	<brief_summary>Hematopoietic stem cell transplantation ( HSCT ) one best , sometimes , option treatment leukemia , particularly patient advanced-stage leukemia . However , relapse rate still high advanced-stage leukemia . It find previous study infusion granulocyte colony-stimulating factor ( G-CSF ) -primed peripheral blood progenitor cell ( GPBPC ) instead non-primed lymphocyte exhibit comparative strong graft-versus-leukemia ( GVL ) effect comparative less incidence GVHD , rarely complicate pancytopenia . When GPBPC infusion combine use short-term immunosuppressant GVHD prophylaxis , incidence fatal GVHD complicate GPBPCI reduce . Our primary data show GPBPCI combine use short-term immunosuppressant feasible patient advance leukemia prevent relapse HLA-mismatched HSCT . The study hypothesis : Prevention relapse use granulocyte colony-stimulating factor-primed peripheral blood progenitor cell follow hematopoietic stem cell transplantation patient advanced-stage acute leukemia - reduce relapse rate - improve survival</brief_summary>
	<brief_title>New Therapy Advanced Stage Leukemia After Stem Cell Transplantation</brief_title>
	<detailed_description>A G-CSF-primed PBPCI plan within day 60 post-transplantation hematologic relapse diagnose patient GVHD occur free GVHD 2 week immunosuppression patient receive GPBPCI day 90 post HSCT . Before administration GPBPCI , serious infection clear serious organ failure could present . The GPBPCI regimen comprise G-CSF-primed PBSCs instead harvest non-primed donor lymphocytes short-term immunosuppressive agent prevention GVHD GPBPCI . Chimerism status examine prophylactic treatment GPBPCI .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>highrisk leukemia HSCT active GVHD early relapse</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>